Get started

Stocksignals

AMD Bullish break-out above the 3-month Resistance.Advanced Micro Devices (AMD) opened (and closed) yesterday above the 3-month Channel Down pattern that started after the October 09 2024 High and that is technically a strong bullish break-out signal. The previous break-out in August 2024, eventually reached the 0.786 Fibonacci extension, which was the October 09 2024 High, before declining again. Even though we are long-term bullish on AMD, as it even kept clear the 1W MA200 (red trend-line), which is its multi-month Support, we expect it to reach at least $160.00 (just below the 0.786 Fib) on the short-term. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:AMDLong
by TradingShot
2
PVRINOX PlungesPVRINOX on the 1-day timeframe demonstrated a sharp bearish move, successfully hitting all targets in a precise short trade setup. Identified using the Risological Swing Trading Indicator , this trade perfectly captured the market's downward momentum. PVRINOX Key Levels: Entry: ₹1520.80 SL: ₹1570.40 TP1: ₹1459.45 ✅ TP2: ₹1360.25 ✅ TP3: ₹1261.05 ✅ TP4: ₹1199.75 ✅ Technical Analysis: The trade initiated at ₹1520.80 with a calculated stop-loss at ₹1570.40, offering an impressive risk-to-reward ratio. The consistent downtrend was confirmed as prices respected the resistance levels marked by the Risological indicator. The achievement of all targets reflects the trade's efficiency and the indicator's accuracy. The break below key support levels and sustained bearish momentum ensured the targets were met seamlessly.
NSE:PVRINOXShort
by ProfitsNinja
TSM: Growth and Charts Align for 15%+ Target?Hey Realistic Traders, Will NYSE:TSM Create a New All-Time High? Let’s Dive In.... TSMC is the world’s largest contract chipmaker. Recent Earning Call reported whooping third quarter revenue of $759.69 billion, marking a YoY increase of 36.5%. The performance is beating the market forecast. Double Digit Revenue Growth is driven by demand for AI Chips especially with major client like NVIDIA & Apple and 3-nanometer &5 nanometer technology in Smartphones. TSMC Chief Financial Officer Huang Renzhao shared optimistic project for the company. TSMC expect Q4 quarterly revenue growth of approximately 13%, sligtly above the market the market expectation. Strong AI-Related demand predicted to persist for year, inlined with the company’s perfomance and expectation. The positive sentiment support our bullish call on NVIDIA. Technical Analysis On the daily timeframe, TSM has remained above the EMA200 line for over a year, maintaining its bullish trend. On August 5, 2024, TSM rebounded impulsively from the EMA200 line after completing an ABC correction pattern, signaling the start of a new bullish wave. The second and fourth corrective waves have retraced to the Fibonacci 0.382 and 0.618 golden ratios, respectively, aligning with Elliott Wave rules that typically indicate further upward movement. In addition to the Elliott Wave analysis, a breakout from a Descending Broadening Wedge pattern has been identified. Such breakouts often signal the continuation of the prevailing market trend. Therefore based on these technical analysis, I foresee a potential upward movement toward the first target at $217.85 or second target at 234.46 This outlook remains valid as long as the price holds above the stop-loss level at 177.95 Support the channel by engaging with the content, using the rocket button, and sharing your opinions in the comments below. Disclaimer: "Please note that this analysis is solely for educational purposes and should not be considered a recommendation to take a long or short position on Taiwan Semiconductor."
NYSE:TSMLong
by financialfreedomgoals101
GameStop (GME) Can We Jump Over $33 to Reach New Heights?Hey there, trading family! Get ready for an exciting journey with GameStop (GME) stock! Right now, GME is like a video game character trying to jump over a big obstacle at $33. If it makes this jump, wow, we might see it zoom up to play between $36.50 and $37.50! It's like reaching a new level in your favorite game. But here's the catch: if GME doesn't make it over $33, it's like falling back to the start of the level, or in this case, dropping back down to hang out between $25 and $27. We'll look at cool charts and listen to what other gamers (I mean, traders!) are saying about GME to help us guess what might happen next. Will GME soar like a high score, or will we have to retry the level? If you found this post useful share, like or tell me your thoughts would love to hear them. Kris/ Mindbloome Exchange Trade What You See
NYSE:GMELong
by Mindbloome-Trading
2
"HDFC Bank Swing Trade: Key Levels & 3-Month Investment Plan"A investment idea for HDFCBANK with a holding period of up to 3 months (till Q1). Here’s the analysis based on the marked levels: Key Levels and Strategy: 1. Entry Point: 1,719.00: Recommended entry level. 2. Take Profit (TP) Targets: TP 1: 1,778.55 TP 2: 1,818.70 TP 3: 1,906.55 (longer-term target). 3. Stop-Loss (SL) Levels: SL: 1,697.25 (first risk level, can act as minor support). Strict SL: 1,671.95 (final stop-loss level to limit risk). Observations: Risk-Reward: This strategy provides a well-defined risk-to-reward ratio, with three potential profit levels. Support Zone: The area around 1,697.25 - 1,671.95 is critical. It might act as strong support if the price drops further. Resistance Levels: 1,778.55: Could face selling pressure as it aligns with prior resistance. 1,818.70: A stronger resistance where bulls need momentum to break through. Recommendation: If the price moves to the entry level (1,719.00), ensure to set your stop-loss and gradually book profits at the mentioned TP levels. Reassess market conditions if it approaches strict SL (1,671.95) to avoid excessive losses. Disclaimer: "I'm not SEBI registered. Please take any trade at your own risk. Market securities are subject to market risks. This is for educational purposes only. Would you like further insights into technical indicators or additional strategies? Thank you! Subscribe and like @Alpha_strike_trader."
NSE:HDFCBANKLong
by Alpha_strike_trader
1
EXXON MOBIL Will it recover the devastating December?Exxon Mobil (XOM) gave us an excellent buy signal on our last idea (September 27 2024, see chart below) as it quickly hit our $120 Target: Since the November 22 2024 (Lower) High though, it had an aggressive sell-of that stopped on the December 20 2024 Low. The price has stabilized for now but hasn't yet gained the necessary momentum to stage a rebound. On the other hand, there are some very encouraging signals that justify going long as the Risk/ Reward Ratio has turned very favorable for buying. The price might not be exactly at the bottom (Higher Lows trend-line) of the Channel Up but the 1W RSI is on the 38.35 Support, which is the exact level where the it bottomed on January 19 2024, on the previous Higher Low. At the same time, the 1D MACD has completed a Bullish Cross, which has always been a solid buy entry below the 0.0 level. As a result, even though the stock may deliver one last pull-back to test the bottom of the 14-month Channel Up, it is worth buying now as the upside is significantly higher. Our Target is the Resistance 2 level at $126.40. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:XOMLong
by TradingShot
2
TESLA How further can it drop??Tesla (TSLA) has clearly overachieved since our previous buy signal (August 15 2024, see chart below), surpassing our $380 Target: The last 3 weeks though has seen overdue weakness on the price action, which was delayed due to the U.S. elections aftermath. The deliveries miss is pulling the price back towards its fair value region and the 1D MA50 (blue trend-line), which has been intact since the October 23 2024 bullish break-out. Tesla has been trading inside a Parabolic Channel for almost a year (since February 2024) and the level that has marked the strongest buy opportunities recently has been the 1D MA100 (green trend-line). Every contact on that level since the August 05 2024 Low, has been a solid buy entry. Parallel to the 1D MA100 contacts, the 1D RSI tends to test its own Support Zone, whose bottoms are aligned and is an additional buy signal. With regards to corrections within this Parabolic Channel, the two major ones have both been -32.65%, an amazing display of symmetry. If the current pull-back also follows that pattern and evolves into another -32.65% Bearish Leg, then it might make contact with the 1D MA100 around the $330 level. Unless the 1D RSI hits its Support Zone earlier, that is technically a fair value for Tesla in our opinion, where heavy buying may commence again. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:TSLAShort
by TradingShot
Suntek realtyFrom the Covid low of 145 zone prices have given a rally for two years and made a high of 590 in Jan'22. From there prices have retraced 50% and made a low of 272 and recovered back to hit new all time high. Prices have made a continuation Head & shoulders pattern whose neckline is 500 zone. Prices have given the breakout the neckline and currently retesting the same. The measured target of the pattern is 950 zone. Prices are likely to continue the uptrend towards 950-1000 zone in the coming months. The key level for the same is 380.
NSE:SUNTECKLong
by TradingSutra
Ai16Z | From Meme to Money making machineai16z is the new star in the meme token galaxy, built on the lightning fast Solana blockchain and launched on the playful daos. fun platform. With AI backing it and a cheeky nod to the a16z VC fund, this token’s got serious meme mentum. Today’s Price Check -Current Price: $1.27 (+5% in the last 24 hours) -All-Time High (ATH): $1.38 (hit on Dec 29, 2024) – just 5.86% below the peak. -Circulating Supply: 1.10 billion tokens (max supply also 1.10 billion). -24-Hour Trading Volume: A whopping $75.84 million. Market Flex ai16z is traded on 24 markets and 14 exchanges, with Gate.io leading the pack. It holds a cozy 0.04% share of the total crypto market, boasting a market cap of $1.43 billion. Oh, and word on the street? It’s on Binance’s radar for a potential listing Riding the Meme Wave Move over, SHIB, PEPE, and DOGE—ai16z is stealing the spotlight in the meme coin market rally. Its lowest price ever? A humble $0.01019 on Nov 3, 2024. Fast forward to now, and it’s up an insane 12,650% from that rock bottom price. The Whale Tale December 28 was a big day for ai16z, thanks to a crypto whale who made some serious moves. This savvy investor withdrew 10M USDC from Coinbase and snagged 13.16M ai16z tokens when they were undervalued on Dec 11. The result? In just two weeks, their $10 million investment ballooned to a jaw-dropping $15.66 million, netting a sweet $5.66 million profit. That’s the kind of whale flex you all dream about. ai16z is proving it’s more than just a meme, it’s a mover and shaker in the Solana ecosystem.
Long
by moonypto
2
Linde plc | LIN Linde, Timeless Excellence Linde is a timeless business with even better stability than other basic materials businesses. The company works in gases and has a near-unbroken EPS growth record of 8% annually Linde is a market leader, and if you invest in the company, you're investing in the world's largest company for industrial gases. The company was originally a result of a takeover of British BOC in 2006, and again the 2018 merger of Linde and Praxair, a US company. On the macro upside, there was a 1) supportive regulatory framework in the USA and in the EU on green opportunities and hydrogen, 2) the Ukraine invasion was also a key catalyst towards the energy transition, 3) the EU chip acts with €43 billion in supporting funds as well as the United States Chips and Science Act development for a value of approximately $52 billion, and 4) higher needs of specialty gas in EV car. Related to the micro upside, the company is more diversified on a GEO revenue basis and sells different product solutions starting from cylinders to bulk liquid. In addition with a follow-up note titled "Positive News Ahead", we reported Linde's lower cost structure with the Frankfort delisting. Aside from removing the dual listing expenses, we positively view this development because US companies' P/E multiple are usually higher compared to the EU one. To support our MACRO buy case recap, in the second quarter, Linde announced two new projects with Evonik and Heidelberg Materials (both companies covered by our internal team). The company signed a long-term agreement to produce green hydrogen for Evonik in a 9-megawatt alkaline electrolyzer plant in Singapore. With Heidelberg, Linde will build a large-scale carbon capture close to the Lengfurt plant in Germany. As a reminder, cement production is estimated to be responsible for around 7% of global in 2022, APD's earnings per share were at $8.38, and Linde's earnings per share were fairly similar at $8.23. For 2023, Air Products and Chemical EPS guide a midpoint at $11.40 while Linde's EPS is forecasted at $13.65. Looking at the ROCE, in Q4 2022, APD stood at 11.7% and Linde at 13.4%. In the last quarter, APD’s ROCE was flat on the two-year comparison, while Linde’s after-tax ROCE reached 24.0%. While there are some business & regional nuances between the two leading companies (for instance, APD is lacking U.S. packaged gas business), here at the Lab, we believe are more inclined toward Linde, particularly when organic growth has been fairly similar. Cross-checking APD and Linde's last quarter results, we should recall that on a comparable basis, the German player volumes were flat with an average selling price up by 8%. On the other hand, APD increased its volume by 6% with an increase in the average selling price of 8% too. APD adj EBITDA grew by 13% while Linde achieved a plus 11%. However, Linde's EU exposure is greater than APD. Therefore, this is supportive of Linde's bottom line. In numbers, excluding the Engineering divisional performance, Linde's EMEA sales reached $2,177 million and represented 29.72% of the company's total sales. Compared to Q1 2022 number, turnover grew by 10% and was driven by a 13% of cost pass-through increase.
LLong
by moonypto
6
Shopify Inc | SHOP & AIShopify stock has seen sideways momentum for the last few weeks despite posting good results in the recent quarter. One of the reasons is the bull run in early 2023 due to which the stock has seen over 60% jump in year-to-date. Shopify has been able to reignite revenue growth in the last few quarters and there are strong tailwinds that can help the company improve its topline. At the same time, Shopify has been able to improve the conversion of Gross Merchandise Value or GMV into revenue due to better services. Shopify’s GMV has increased 11x between the last quarter of 2016 and the last quarter of 2022. During this time, Shopify’s quarterly revenue base has increased from $130 million to $1.7 billion or 13x. Shopify’s GMV for 2022 was $195 billion and rapid growth in this key metric should help the company improve monetization. The company has also undertaken some cost-cutting which is having a positive impact on the bottom line. Analysts have forecasted Shopify’s EPS at $1 for fiscal 2025 which means that the stock is trading 60 times the EPS estimate of 2025. However, better monetization and focus on cost optimization could help the company deliver good EPS growth in the next few quarters. The PS ratio is also at 12 which is significantly lower than the pre-pandemic years. Shopify stock can deliver good returns in the long term as the company adds new services and improves its GMV growth trajectory. Shopify reported a GMV of $5.5 billion in December 2016 quarter. This has increased to $60 billion in the recent December 2022 quarter. Hence, Shopify’s GMV has increased to 11 times within the last seven years. On the other hand, Shopify’s revenue during the December quarter has increased by 13 times, from $130 million to $1.7 billion. This growth trend shows that the company is able to convert more GMV into actual revenue. One of the main reasons behind this trend is that Shopify is adding new services and it can charge customers a higher commission for these services. Shopify’s GMV for 2022 was a staggering $195 billion. The company has been able to reignite revenue growth in the last few quarters. The YoY revenue growth hit a bottom of 15% in June 2022. Since then the YoY revenue growth has picked up again as the company faces easier comps. In the recent quarter, the company reported YoY revenue growth of over 30% which is quite high when we consider that the GMV base of Shopify is more than $200 billion. The revenue growth will not build a bullish momentum for the stock unless the company can deliver sustainable profitability. During the pandemic years, Shopify’s revenue growth and high EPS helped the stock reach its peak. The company would need to focus on profitability in the next few quarters in order to rebuild a long-term bullish rally. Shopify has divested from its logistics business which should help improve the bottom line. We should also see better monetization of current services as the company tries to build new AI tools. The EPS estimates for 2 fiscal years ahead have steadily improved in the last few quarters. According to current consensus, Shopify should be able to deliver EPS of $1 in fiscal year 2025. However, it is highly likely that Shopify will beat these estimates as the company launches new initiatives to improve monetization of its massive GMV base. Shopify’s trailing twelve months EPS during the peak of the pandemic went to $2.6. If the company can get close to this EPS rate by 2025, we should see a significant bullish run in the stock. The recent cost-cutting should also help the company improve the bottom line. We have seen a similar trend in all the Big Tech companies who have reported a rapid growth in EPS as their headcount was reduced. While most analysts agree over the long-term revenue growth potential of Shopify, some of them are wary of the pricey valuation of the stock. Shopify is trading at 12 times its PS ratio. This is quite high when we compare with most of the other tech players and even Shopify’s peer like Wix (WIX), Etsy (ETSY), and others. However, it should be noted that Shopify’s PS ratio is significantly lower than the average PS multiple prior to the pandemic when the stock had an average PS ratio of over 20. Shopify’s revenue estimates for 2 fiscal years ahead is close to $10 billion which is equal to annualized revenue growth of over 25%. If we look at this metric, Shopify stock is trading at 7 times the revenue estimate of fiscal year 2025. This looks reasonable if the company can also manage to improve its EPS trend over the next few years. The long-term tailwind from ecommerce growth is still very strong. Shopify will benefit from an increase in GMV and a higher ecommerce market share in key markets. This should help the company gain pricing leverage over other competitors and also improve its monetization momentum Shopify has reported a faster revenue growth rate compared to its GMV growth in the last few years. This shows that the company is able to charge higher rate for additional services. There has been an acceleration in revenue growth over the last few quarters. Shopify has also divested from logistics services which were pulling down the profitability of the company. Shopify could deliver over 20% YoY revenue growth for the next few years as the company gains from strong tailwinds within the ecommerce business. If Shopify regains its earlier ttm EPS of $2 by 2025, we could see a strong bull run within the stock. While the stock is not cheap, it seems to be reasonably valued and longer-term investors could gain a better return from Shopify, making the stock a Buy at current price.
NYSE:SHOPLong
by moonypto
2
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
COINBASE approaching the 1W MA50 and turns into a Buy again.Coinbase (COIN) has gone a long way since our September 09 buy signal (see chart below): Even though it marginally missed the $360 Target, the pattern served in an excellent way those investors who bought at the bottom of its dominant 2-year Channel Up. The September - December Bullish Leg was by a narrow margin, the shortest (+141.45%) of Coinbase's total 5 major rallies within this pattern. As the price is yet again approaching the 1W MA50 (blue trend-line), it is gradually turning into a Buy opportunity again. Even though the shortest Bearish Leg has been -38.74% and that currently places the projected bottom level a little over $215, the 1W RSI has already broken below its MA (yellow trend-line), which has been the ultimate buy signal on all previous technical corrections with the exception of last April. As a result, there are more probabilities to see COIN resume the 2-year bullish trend, with the Risk/ Reward Ratio (RRR) turning favorable again. A Dollar-cost-averaging strategy is also suited for those seeking less risk. Our Target from now on is $500, which represents a +141.45% rise (as mentioned above, the shortest within the Channel Up). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:COIN
by TradingShot
1
Aadhar Housing looks enticing. Aadhar Housing Finance Ltd. engages in the provision of home loans. It also offers loans to customers including individuals, Companies, Corporations, Societies or Association of Persons for purchase; construction; repair and renovation of residential property. Aadhar Housing Finance Ltd. CMP is 434.25. The positive aspects of the company are Stocks Outperforming their Industry Price Change in the Quarter, Decrease in Provision in recent results, Company with Zero Promoter Pledge and Annual Net Profits improving for last 2 years. The Negative aspects of the company are Moderately High Valuation (P.E. = 22.4), Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years and Companies with high market cap, lower public shareholding. Entry can be taken after closing above 439 Targets in the stock will be 453, 468 and 480. The long-term target in the stock will be 495 and 518. Stop loss in the stock should be maintained at Closing below 399 or 375 depending upon your risk taking ability. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:AADHARHFCLong
by Happy_Candles_Investment
Inox green looking clean. Inox Green Energy Services Ltd. provides wind power operation and maintenance services. The company is engaged in the business of providing long-term O&M services for wind farm projects, Inox Green Energy Services Ltd. CMP is 175.19. The positive aspects of the company are Company with Low Debt, Company able to generate Net Cash - Improving Net Cash Flow for last 2 years, Company with decreasing Promoter pledge, Annual Profit Growth higher than Sector Profit Growth and Negative to Positive growth in Sales and Profit. The Negative aspects of the company are extremely Highest Valuation (P.E. = 214.8) and Increasing Trend in Non-Core Income. Entry can be taken after closing above 176 Targets in the stock will be 186 and 199. The long-term target in the stock will be 209 and 223. Stop loss in the stock should be maintained at Closing below 159 or 140 depending upon your risk taking ability. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:INOXGREENLong
by Happy_Candles_Investment
DJT: Will It Break $33.85 or $38.55 First? DJT is at a tipping point, and it could go either way. Here’s what to watch so you’re ready for the next big move. 1) If DJT Drops Below $33.85 If this level breaks, things could get rough. Here’s what might happen: -$28–$26: This is the first stop where the price might chill for a bit. -$10: If the selling gets heavy, this is where we could end up. 2) If DJT Pops Above $38.55 If the bulls take charge, it could be time to ride the wave higher: A break above $38.55 could spark a nice rally and push the price upward. What’s the Plan? -Keep an eye on $33.85 and $38.55—they’re the magic numbers. -Be patient and wait for a clear move before jumping in. If this makes sense, toss me a like or follow. Got questions about DJT or another stock you’re stuck on? Hit me up in the DMs—I’m here to help. And hey, if you’re feeling burned out or stressed about trading, let’s talk. I’m all about helping you find your balance and keeping things sustainable. Chill, stay focused, and let’s catch the next wave together! Kris/ Mindbloome Exchange Trade What You See
NASDAQ:DJT
by Mindbloome-Trading
2
QMCO at a Make-or-Break Moment: 5 Key Levels to Watch Now Morning Trading Family QMCO is approaching a critical crossroads, and the next move could bring some serious action. Let’s break it down with key levels and what they mean for traders. If we break below $65.46 The outlook turns bearish. These are the levels to watch on the way down: $60: First stop. This is where buyers might step in to test the waters. $55: A deeper pullback that could bring more attention from the market. $52: A critical level. If we hit this, it’s time to reevaluate what’s next. If we break above $68.37 This would signal a potential shift in behavior, and the bulls might take over. Here’s what could happen: $70: The next challenge for price to clear. $73: A key level that could act as resistance. Above $73? That’s the green light for a long position. If the price moves past $73, it’s likely that the trend has flipped, and we could see much higher levels. What You Can Do -Keep a close eye on $65.46 and $68.37. These levels are your signals for the next move. -Plan ahead—set stop-loss levels to manage your risk. -Stick to your strategy and don’t rush into trades without confirmation. If you found this helpful, don’t forget to follow, like, or boost this video. Have questions about other charts or feeling stuck with trading? Send me a DM—I’m here to help! Kris/ Mindbloome Exchange Trade What You See
NASDAQ:QMCO
by Mindbloome-Trading
MICROSOFT ahead of an expansion similar to the Internet BubbleMicrosoft (MSFT) has been practically neutral for half the year (last 6 months) as since the July 2024 High, it has been trading sideways, unable to catch a rally for a new All Time High (ATH). This consolidation is technically no different that the July - December 1995 sideways sequence (green circle). As you can see, the two fractals since their September 2014 and September 1987 starting points respectively, have been virtually identical, especially in terms of 1M RSI. The reason for these striking similarities is simple. The market is currently unfolding the A.I. Bubble just like it did with the Internet (Dotcom Bubble) in the 1990s. The two technological revolutions are not the same but the A.I. has the capacity to change the socioeconomic market structure just like the Internet did. Based on that analogy, the current 6-month consolidation technically serves as a Re-accumulation Phase following the first part of the A.I. Bubble just like July - Dec 1995 was after the first past of the Internet Bubble up to the 0.382 Time Fibonacci level. If those similarities are extended until the end, then we should not see such a long consolidation again until the 0.618 Fib, when the final past of the Bubble will begin. This chart comparison doesn't serve at giving us a specific Target for this Cycle but rather encourage investors that despite the seeming lack of direction these past 6 months, Microsoft is a strong buy opportunity long-term. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:MSFTLong
by TradingShot
1
MICROSTRATEGY Is it shifting towards a new paradigm?Microstrategy (MSTR) is defying all odds during this bull run and recently it achieved perhaps its most important one: it broke above its All Time High (ATH) of $335.00 registered in March 2000. This historic feat took place on the same month (November) that it broke and closed above its historical Channel Up pattern, which has been dictating its trend since the bottom of the Dotcom Bubble correction in 2002. This is perhaps ushering a new era for the company. Along with Bitcoin it may be shifting to a new paradigm and the uptrend may be accelerated in a similar way as it did in 1998 - 2000. Technically we will be in a position to know that if the current pull-back bounces of the top of the former historic Channel Up. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:MSTRLong
by TradingShot
7